These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

479 related articles for article (PubMed ID: 25541967)

  • 21. Engineering HIV-resistant human CD4+ T cells with CXCR4-specific zinc-finger nucleases.
    Wilen CB; Wang J; Tilton JC; Miller JC; Kim KA; Rebar EJ; Sherrill-Mix SA; Patro SC; Secreto AJ; Jordan AP; Lee G; Kahn J; Aye PP; Bunnell BA; Lackner AA; Hoxie JA; Danet-Desnoyers GA; Bushman FD; Riley JL; Gregory PD; June CH; Holmes MC; Doms RW
    PLoS Pathog; 2011 Apr; 7(4):e1002020. PubMed ID: 21533216
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficient clinical scale gene modification via zinc finger nuclease-targeted disruption of the HIV co-receptor CCR5.
    Maier DA; Brennan AL; Jiang S; Binder-Scholl GK; Lee G; Plesa G; Zheng Z; Cotte J; Carpenito C; Wood T; Spratt SK; Ando D; Gregory P; Holmes MC; Perez EE; Riley JL; Carroll RG; June CH; Levine BL
    Hum Gene Ther; 2013 Mar; 24(3):245-58. PubMed ID: 23360514
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preintegration HIV-1 inhibition by a combination lentiviral vector containing a chimeric TRIM5 alpha protein, a CCR5 shRNA, and a TAR decoy.
    Anderson JS; Javien J; Nolta JA; Bauer G
    Mol Ther; 2009 Dec; 17(12):2103-14. PubMed ID: 19690520
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CRISPR/Cas9-Mediated CCR5 Ablation in Human Hematopoietic Stem/Progenitor Cells Confers HIV-1 Resistance In Vivo.
    Xu L; Yang H; Gao Y; Chen Z; Xie L; Liu Y; Liu Y; Wang X; Li H; Lai W; He Y; Yao A; Ma L; Shao Y; Zhang B; Wang C; Chen H; Deng H
    Mol Ther; 2017 Aug; 25(8):1782-1789. PubMed ID: 28527722
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Engineering HIV-1-resistant T-cells from short-hairpin RNA-expressing hematopoietic stem/progenitor cells in humanized BLT mice.
    Ringpis GE; Shimizu S; Arokium H; Camba-Colón J; Carroll MV; Cortado R; Xie Y; Kim PY; Sahakyan A; Lowe EL; Narukawa M; Kandarian FN; Burke BP; Symonds GP; An DS; Chen IS; Kamata M
    PLoS One; 2012; 7(12):e53492. PubMed ID: 23300932
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multiplexed
    Ophinni Y; Miki S; Hayashi Y; Kameoka M
    Viruses; 2020 Oct; 12(11):. PubMed ID: 33126728
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Downregulation of the CCR5 beta-chemokine receptor and inhibition of HIV-1 infection by stable VA1-ribozyme chimeric transcripts.
    Cagnon L; Rossi JJ
    Antisense Nucleic Acid Drug Dev; 2000 Aug; 10(4):251-61. PubMed ID: 10984119
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting both viral and host determinants of human immunodeficiency virus entry, using a new lentiviral vector coexpressing the T20 fusion inhibitor and a selective CCL5 intrakine.
    Petit N; Dorgham K; Levacher B; Burlion A; Gorochov G; Marodon G
    Hum Gene Ther Methods; 2014 Aug; 25(4):232-40. PubMed ID: 25045917
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lentiviral transduction of human T-lymphocytes with a RANTES intrakine inhibits human immunodeficiency virus type 1 infection.
    Schroers R; Davis CM; Wagner HJ; Chen SY
    Gene Ther; 2002 Jul; 9(13):889-97. PubMed ID: 12080383
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Complete knockdown of CCR5 by lentiviral vector-expressed siRNAs and protection of transgenic macrophages against HIV-1 infection.
    Anderson J; Akkina R
    Gene Ther; 2007 Sep; 14(17):1287-97. PubMed ID: 17597795
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CRISPR/Cas9 genome editing of CCR5 combined with C46 HIV-1 fusion inhibitor for cellular resistant to R5 and X4 tropic HIV-1.
    Khamaikawin W; Saisawang C; Tassaneetrithep B; Bhukhai K; Phanthong P; Borwornpinyo S; Phuphuakrat A; Pasomsub E; Chaisavaneeyakorn S; Anurathapan U; Apiwattanakul N; Hongeng S
    Sci Rep; 2024 May; 14(1):10852. PubMed ID: 38741006
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lentivector Knockdown of CCR5 in Hematopoietic Stem and Progenitor Cells Confers Functional and Persistent HIV-1 Resistance in Humanized Mice.
    Myburgh R; Ivic S; Pepper MS; Gers-Huber G; Li D; Audigé A; Rochat MA; Jaquet V; Regenass S; Manz MG; Salmon P; Krause KH; Speck RF
    J Virol; 2015 Jul; 89(13):6761-72. PubMed ID: 25903342
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multiplex CRISPR/Cas9-based genome engineering from a single lentiviral vector.
    Kabadi AM; Ousterout DG; Hilton IB; Gersbach CA
    Nucleic Acids Res; 2014 Oct; 42(19):e147. PubMed ID: 25122746
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TALEN-Mediated Knockout of CCR5 Confers Protection Against Infection of Human Immunodeficiency Virus.
    Shi B; Li J; Shi X; Jia W; Wen Y; Hu X; Zhuang F; Xi J; Zhang L
    J Acquir Immune Defic Syndr; 2017 Feb; 74(2):229-241. PubMed ID: 27749600
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gene editing using a zinc-finger nuclease mimicking the CCR5Δ32 mutation induces resistance to CCR5-using HIV-1.
    Badia R; Riveira-Muñoz E; Clotet B; Esté JA; Ballana E
    J Antimicrob Chemother; 2014 Jul; 69(7):1755-9. PubMed ID: 24651827
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Establishment of mouse leukemia cell lines expressing human CD4/CCR5 using lentiviral vectors.
    Li YJ; ZhuGe FY; Zeng CC; He JY; Tan N; Liang J
    Virus Genes; 2017 Apr; 53(2):197-204. PubMed ID: 28028680
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A highly efficient short hairpin RNA potently down-regulates CCR5 expression in systemic lymphoid organs in the hu-BLT mouse model.
    Shimizu S; Hong P; Arumugam B; Pokomo L; Boyer J; Koizumi N; Kittipongdaja P; Chen A; Bristol G; Galic Z; Zack JA; Yang O; Chen IS; Lee B; An DS
    Blood; 2010 Feb; 115(8):1534-44. PubMed ID: 20018916
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Resistance to human immunodeficiency virus type 1 (HIV-1) generated by lentivirus vector-mediated delivery of the CCR5{Delta}32 gene despite detectable expression of the HIV-1 co-receptors.
    Jin Q; Marsh J; Cornetta K; Alkhatib G
    J Gen Virol; 2008 Oct; 89(Pt 10):2611-2621. PubMed ID: 18796731
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The therapeutic application of CRISPR/Cas9 technologies for HIV.
    Saayman S; Ali SA; Morris KV; Weinberg MS
    Expert Opin Biol Ther; 2015 Jun; 15(6):819-30. PubMed ID: 25865334
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In Vivo Excision of HIV-1 Provirus by saCas9 and Multiplex Single-Guide RNAs in Animal Models.
    Yin C; Zhang T; Qu X; Zhang Y; Putatunda R; Xiao X; Li F; Xiao W; Zhao H; Dai S; Qin X; Mo X; Young WB; Khalili K; Hu W
    Mol Ther; 2017 May; 25(5):1168-1186. PubMed ID: 28366764
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.